Evidence map›Paper›PMID 35260646›Full record

ArticleScientific reports2022

Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein.

Lasse Reimer, Caroline Haikal, Hjalte Gram, Vasileios Theologidis, Gergo Kovacs, Harm Ruesink, Andreas Baun, Janni Nielsen, Daniel Erik Otzen, Jia-Yi Li and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Organosulfur Compounds: Potential Therapeutics for Parkinson's Disease.CNS & neurological disorders drug targets · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Lasse ReimerDanish Research Institute of Translational Neuroscience - DANDRITE, Aarhus University, Aarhus C, Denmark. lasse.reimer@biomed.au.dk.
Caroline HaikalNeural Plasticity and Repair Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden.
Hjalte GramDanish Research Institute of Translational Neuroscience - DANDRITE, Aarhus University, Aarhus C, Denmark.
Vasileios TheologidisDanish Research Institute of Translational Neuroscience - DANDRITE, Aarhus University, Aarhus C, Denmark.
Gergo KovacsDanish Research Institute of Translational Neuroscience - DANDRITE, Aarhus University, Aarhus C, Denmark.
Harm RuesinkDanish Research Institute of Translational Neuroscience - DANDRITE, Aarhus University, Aarhus C, Denmark.
Andreas BaunDanish Research Institute of Translational Neuroscience - DANDRITE, Aarhus University, Aarhus C, Denmark.
Janni NielsenInterdisciplinary Nanoscience Center - iNANO, Aarhus University, Aarhus C, Denmark.
Daniel Erik OtzenInterdisciplinary Nanoscience Center - iNANO, Aarhus University, Aarhus C, Denmark.
Jia-Yi LiNeural Plasticity and Repair Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden.
Poul Henning JensenDanish Research Institute of Translational Neuroscience - DANDRITE, Aarhus University, Aarhus C, Denmark.
Aarhus University · DKLund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dimethyl sulfoxide (DMSO) is a highly utilized small molecule that serves many purposes in scientific research. DMSO offers unique polar, aprotic and amphiphilic features, which makes it an ideal solvent for a wide variety of both polar and nonpolar molecules. Furthermore, DMSO is often used as a cryoprotectant in cell-based research. However, recent reports suggest that DMSO, even at low concentration, might interfere with important cellular processes, and cause macromolecular changes to proteins where a shift from α-helical to β-sheet structure can be observed. To investigate how DMSO might influence current research, we assessed biochemical and cellular impacts of DMSO treatment on the structure of the aggregation-prone protein α-synuclein, which plays a central role in the etiology of Parkinson's disease, and other brain-related disorders, collectively termed the synucleinopathies. Here, we found that addition of DMSO increased the particle-size of α-synuclein, and accelerated the formation of seeding-potent fibrils in a dose-dependent manner. These fibrils made in the presence of DMSO were indistinguishable from fibrils made in pure PBS, when assessed by proteolytic digestion, cytotoxic profile and their ability to seed cellular aggregation of α-synuclein. Moreover, as evident through binding to the MJFR-14-6-4-2 antibody, which preferentially recognizes aggregated forms of α-synuclein, and a bimolecular fluorescence complementation assay, cells exposed to DMSO experienced increased aggregation of α-synuclein. However, no observable α-synuclein abnormalities nor differences in neuronal survival were detected after oral DMSO-treatment in either C57BL/6- or α-synuclein transgenic F28 mice. In summary, we demonstrate that low concentrations of DMSO makes α-synuclein susceptible to undergo aggregation both in vitro and in cells. This may affect experimental outcomes when studying α-synuclein in the presence of DMSO, and should call for careful consideration when such experiments are planned.

Indexed as

Parkinson DiseaseSynucleinopathiesalpha-SynucleinAnimalsDimethyl SulfoxideMiceMice, Inbred C57BLMice, Transgenicalpha-SynucleinDimethyl Sulfoxide

Identifiers

PMID35260646
PMCPMC8904838
OpenAlexW4220671370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.